Immunovaccine Named to 2018 OTCQX Best 50
January 24 2018 - 8:00AM
Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage
immuno-oncology company, today announced that it has been named to
the 2018 OTCQX® Best 50, a ranking of top performing companies
traded on the OTCQX Best Market last year.
The OTCQX Best 50 is an annual ranking of the top 50 U.S. and
international companies traded on the OTCQX market. The ranking is
calculated based on an equal weighting of one-year total return and
average daily dollar volume growth in the previous calendar year.
Companies in the 2018 OTCQX Best 50 were ranked based on their
performance in 2017.
“We are very pleased to be recognized as one of the 2018 OTCQX
Best 50, as our brethren on this list are among some of the most
renowned and fastest growing companies in the world,” said Frederic
Ors, Immunovaccine’s Chief Executive Officer. “2017 was a pivotal
year for Immunovaccine, as we transitioned from a platform-based
biotechnology company, to a clinical-stage biopharmaceutical
organization, with multiple assets advancing in our pipeline. We
are grateful to our investors for their continued support, which we
believe is reflected in this designation.”
For the complete 2018 OTCQX Best 50 ranking, visit
http://bit.ly/OTCQX-best50-2018.
The OTCQX Best Market offers transparent and efficient trading
of established, investor-focused U.S. and global companies. To
qualify for the OTCQX market, companies must meet high financial
standards, follow best practice corporate governance, demonstrate
compliance with U.S. securities laws and have a professional
third-party sponsor introduction. The companies found on OTCQX are
distinguished by the integrity of their operations and diligence
with which they convey their qualifications.
About
ImmunovaccineImmunovaccine Inc. is a clinical-stage
biopharmaceutical company dedicated to making immunotherapy more
effective, more broadly applicable, and more widely available to
people facing cancer and infectious diseases. Immunovaccine
develops T cell activating cancer immunotherapies and infectious
disease vaccines based on DepoVax™, the Company’s patented platform
that provides controlled and prolonged exposure of antigens and
adjuvant to the immune system. Immunovaccine has advanced two T
cell activation therapies for cancer through Phase 1 human clinical
trials and is currently conducting a Phase 1b study with Incyte
Corporation assessing lead cancer therapy, DPX-Survivac, as a
combination therapy in ovarian cancer. The Company is also
exploring additional applications of DepoVax™, including DPX-RSV,
an innovative vaccine candidate for respiratory syncytial virus
(RSV), which has recently completed a Phase 1 clinical trial.
Immunovaccine also has ongoing clinical projects to assess the
potential of DepoVax™ to address malaria and the Zika virus.
Connect at www.imvaccine.com.
Immunovaccine Forward-Looking StatementsThis
press release contains forward-looking information under applicable
securities law. All information that addresses activities or
developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based
on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a
representation that any of the plans will be achieved. Actual
results may differ materially from those set forth in this press
release due to risks affecting the Company, including access to
capital, the successful completion of clinical trials and receipt
of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press
release except as required by law.
Contacts for Immunovaccine:
MEDIA Mike Beyer, Sam Brown
Inc.T: (312) 961-2502 E: mikebeyer@sambrown.com
INVESTOR RELATIONSPierre Labbé, Chief
Financial OfficerT: (902) 492-1819 E:
info@imvaccine.com
Patti Bank, Managing Director, Westwicke
PartnersO: (415) 513-1284T: (415) 515-4572 E:
patti.bank@westwicke.com
IMV (TSX:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMV (TSX:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024